Protocol Ledger

NCT06409650 · Phase II · COMPLETED

To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia

Interventional Phase II clinical trial protocol NCT06409650 sponsored by Suzhou Koshine Biomedica in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-11-09 Enrollment: 160 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06409650
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)160 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06409650
Protocol FieldVerified Registry Value
NCT IdentifierNCT06409650
Consolidated Lead SponsorSuzhou Koshine Biomedica
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment160 participants (ACTUAL)
Registered Start Date2021-11-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI